Company Overview of Lineagen, Inc.
Lineagen, Inc. provides genetic evaluation services in autism and developmental delay. The company focuses on genetic disorders, such as autism, multiple sclerosis, and chronic obstructive pulmonary disease. It provides FirstStep, which provides physicians with integrated genetic testing, counseling, and developmental screening services to aid in the clinical evaluation; and M-CHAT, an autism screening tool. The company also offers counseling services. It serves healthcare professionals, physicians, and individuals. The company was formerly known as GenData Research Corporation and changed its name in January 2005. Lineagen, Inc. was founded in 2002 and is based in Salt Lake City, Utah.
423 Wakara Way
Salt Lake City, UT 84108
Founded in 2002
Key Executives for Lineagen, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Senior Director of Product Management
Chief Commercialization Officer
Compensation as of Fiscal Year 2014.
Lineagen, Inc. Key Developments
Lineagen, Inc. Announces Board Appointments
Feb 18 15
Lineagen, Inc. announced the closing of the second and final tranche of its $15.8 million Series C round of financing. David S. Kabakoff, Ph.D., partner of HeathQuest Capital, and David Fitzgerald of Petra Capital have joined the Lineagen Board of Directors in conjunction with the financing.
Lineagen, Inc. Announces Identification of 39 Genetic Variants as Novel Risk Factors for Developing Autism Spectrum Disorder
Feb 26 14
Lineagen, Inc. announced the publication of the first major study in autism spectrum disorder (ASD) to apply a unique research approach that identified 39 variants in 36 genes, which may confer a genetic risk of developing ASD. This approach -haplotype sharing in multi-generational families from the Utah Population Database (UPDB) -opens the door to more efficient elucidation of ASD gene risk variants and more powerful genetic diagnostic testing to assist in the clinical evaluation of individuals with ASD and related disorders of childhood development. Researchers affiliated with The Children's Hospital of Philadelphia (CHOP), the University of Utah (Utah), Golden Helix, Inc., and Lineagen participated in the study, which was designed to detect genetic variants that confer risk of developing ASD in large multi-generational families, and then testing those discoveries in a broader population of unrelated individuals with ASD. The results showed that 11 of the familial gene variants also confer a genetic risk of developing ASD in the general population. Importantly, three genetic variants discovered by Lineagen may be causal, as they were not detected in gene sequences from more than 10,000 individuals without a diagnosis of ASD. One of these variants was identified in the RAB11FIP5 gene that encodes a brain protein involved with synaptic glutamate receptor recycling, among other functions. Two separate variants were identified in the AKAP9 gene, a member of a larger gene family that independent studies have shown to be integral to many biological pathways implicated in the development of ASD. Results from Lineagen's study were published in the current issue of Molecular Autism.
Lineagen, Inc. Presents at 2014 Autism Investment Conference, Mar-04-2014 08:45 AM
Feb 24 14
Lineagen, Inc. Presents at 2014 Autism Investment Conference, Mar-04-2014 08:45 AM. Venue: Bently Reserve, 301 Battery St, San Francisco, CA 94111, United States. Speakers: Michael S. Paul, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|